Mauna Kea Technologies SA (MKEAF PINK) stock market data APIs
$0.3725
0(0%)
as of June 11, 2025
Try our APIs with
free plan!
Mauna Kea Technologies SA Financial Data Overview
Mauna Kea Technologies SA, a medical device company, manufactures and sells medical devices in Europe and internationally. It offers range of medical devices in gastroenterology, pulmonology, and urology areas. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform which enables physicians to monitor progression of disease over time, assess point-in-time reactions, classify indeterminate areas, and guide surgical interventions. The company was incorporated in 2000 and is headquartered in Paris, France.
Prev. Close
0.3725
Open
0.3725
High
0.3725
Low
0.3725
52 wk Range
0.37-0.37
Market Cap
25 875 K
Shares Outstanding
69 932 K
Revenue
8 415 K
EPS
-0.1294
Beta
1.051
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mauna Kea Technologies SA data using free add-ons & libraries
Get Mauna Kea Technologies SA Fundamental Data
Mauna Kea Technologies SA Fundamental data includes:
- Net Revenue: 8 415 K
- EBITDA: -5 475 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mauna Kea Technologies SA News
New
Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level
Recce Pharmaceuticals Dose increase of R327 Dose increase of R327 Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good ...
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
Recce Pharmaceuticals SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleas...
Mauna Kea Technologies Provides Business Update
Corporate resources focused on highest value clinical applications Significant reduction in operating expenses implemented Cash runway now extended to Q4 2023 PARIS & BOSTON, January 13, 2022--(BUS...
Breaking down what tax breaks companies get
Yahoo Finance’s Rick Newman and Julie Hyman discuss the corporate tax debate.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
